Charles River Laboratories International (NYSE:CRL) Given New $155.00 Price Target at Mizuho

Charles River Laboratories International (NYSE:CRL) had its price objective decreased by analysts at Mizuho from $175.00 to $155.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. Mizuho’s price objective points to a potential upside of 25.54% from the stock’s previous close.

Several other research firms also recently issued reports on CRL. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their price target for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. Bank of America cut their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, JPMorgan Chase & Co. lowered their target price on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and an average target price of $183.62.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $123.47 on Wednesday. The firm has a market cap of $6.06 billion, a price-to-earnings ratio of 823.13, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company’s fifty day moving average is $160.28 and its 200-day moving average is $179.09. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a 12 month low of $122.06 and a 12 month high of $258.56.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. During the same period last year, the company earned $2.46 earnings per share. The business’s revenue was down 1.1% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Birgit Girshick acquired 1,514 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the acquisition, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Rothschild Investment LLC grew its holdings in shares of Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock worth $26,000 after purchasing an additional 144 shares during the last quarter. Versant Capital Management Inc grew its stake in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares in the last quarter. Optiver Holding B.V. bought a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $37,000. Finally, GeoWealth Management LLC boosted its holdings in shares of Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after acquiring an additional 190 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).